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Background: Cognitive dysfunction which characterizes dementia is reportedly caused by 
multiple factors including oxidant-antioxidant imbalance, inflammation, alteration in synaptic 
neurotransmission. Despite the arrays of drugs available in managing dementia, it appears no 
single drug can effectively treat dementia. Since it is multifactorial, combining potential drugs 
may provide neuroprotective impact. As such, this study investigated the neuroprotective effects 
of melatonin and vitamin C on scopolamine model of cognitive impairment in rats and the 
possible mechanism of action. Methods: Thirty male Wistar rats were divided to receive either 
normal saline (5 ml/kg, p.o), scopolamine (1 mg/kg, i.p.), donepezil (2 mg/kg, p.o), melatonin 
(10 mg/kg, p.o), vitamin C (100 mg/kg. p.o) or melatonin plus vitamin C. Cognitive impairment 
was induced by daily injection of scopolamine (1 mg/kg, i.p.), after which different treatment 
regimen were administered for 15 days. Spatial memory was assessed using Morris Water Maze 
and modified light and dark box. The brain was processed for malondialdehyde (MDA), reduced 
glutathione (GSH) and acetylcholinesterase (AchE) activity. Results: Scopolamine-treated rats 
with no intervention showed impaired learning and memory as depicted by a significant (p<0.05) 
increase in escape latency, reduction in the frequency of visit to the escape aperture, increased 
MDA, decreased GSH and elevated acetylcholinesterase activity when compared to other 
groups. Interventions with melatonin or/and vitamin C reversed these responses respectively. 
The melatonin plus vitamin C treated group compared favorably with donepezil (reference 
group). Conclusion: Melatonin and vitamin C show neuroprotective effect in attenuating 
cognitive impairment in scopolamine-induced model by modulating oxidative stress pathway 
and enhancing cholinergic neurotransmission.  
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INTRODUCTION   
 Dementia is a progressive disorder characterized by 
gradual decline of mental and intellectual abilities. It 
interferes with social or occupational functioning such 
that as the disease progresses, the ability to function 
independently of an affected individual deteriorates due 
to memory loss and impaired cognitive ability (Tewari 
et al., 2018). Globally, World Health Organization 
(WHO) estimated that about 5-8% of the general 







impairment, with approximately 60% living in low  
and middle-income countries. Annually, there about 10   
million new cases (WHO, 2019). Therefore, it is 
imperative to curb the progression of cognitive decline 
before it crosses the threshold to dementia.  
Involvement of oxidative stress in the pathogenesis of 
cognitive impairment has been reported. The role of 
oxidative stress in many neurodegenerative diseases is 
not shocking because the brain is rich in fatty acids, 
consumes lot of oxygen and deficient of endogenous 
antioxidants. These make it highly susceptible to 
reactive oxygen species (ROS) (Uttara et al., 2009). 
Multiple lines of evidence indicate that oxidative stress
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does not only participate in cognitive impairment but 
plays an important role in inducing and activating 
multiple cell signaling pathways that contribute to the 
formation of toxic substances which promotes the 
development of dementia. Due to the increasing 
evidence that cognitive impairment is mediated by 
oxidative stress (Gil-Yong et al., 2017), cumulative lines 
of evidence have demonstrated that consumption of 
antioxidant-rich foods can enhance cognitive 
performance (Ataie et al., 2010; Craggs and Kalaria, 
2011; Valls-Pedret et al., 2013).  
 
Melatonin is an amphiphilic tryptophan-derived 
indolamine which has a free radical scavenging, and 
antioxidant effects (Hardeland et al., 1993). It scavenges 
reactive oxygen and nitrogen species and increases 
antioxidant defenses, thus it prevents tissue damage and 
blocks transcriptional factors of pro-inflammatory 
cytokines. Melatonin has beneficial effects including 
stimulation of antioxidant enzymes, inhibition of lipid 
peroxidation, and contributes to protection against 
oxidative damages (Manchester et al., 2015). 
Endogenous melatonin secretion is regulated by the 
circadian clock and by light/dark cycles. Through the 
indirect pathway, light influences sleep and secondarily 
influences mood and hippocampal-dependent cognition. 
Studies have shown that melatonin can positively 
influence cognition in adults with mild cognitive 
impairment (Furio et al., 2007; Cardinali et al., 2012) 
In addition, exogenous melatonin has been found to be 
beneficial in improving certain aspects of cognitive 
function in elderly people (Peck et al., 2004), in various 
animal models such as Alzheimer’s disease (AD) (Xian 
et al., 2002; Feng et al., 2004; Olcese et al., 2009).  
Vitamin C, also known as ascorbic acid, is an essential 
nutrient involved in the repair of tissue and the 
enzymatic production of certain neurotransmitters. It is 
required for the functioning of several enzymes and is 
important for immune system function. It also functions 
as an antioxidant (Linus, 2019). The antioxidant effect 
of vitamin C has been well documented (Duarte and 
Lunec, 2005). It is an important water soluble 
antioxidant which is reported to neutralize ROS and 
reduce the oxidative stress (Verma et al., 2007). 
Antioxidants have been reported to prevent oxidative 
damage caused by the generation of free radicals. 
Oxidative stress is a culprit in the pathogenesis of 
various neurodegenerative disorders (Patockova et al., 
2003). Despite the availability of reports that support the 
memory enhancing effects of either melatonin or vitamin 
C and these effects have been strongly linked to their 
antioxidant capacities, yet there is no available evidence 
that combination of melatonin and vitamin C might be 
beneficial in cognitive impairment. As such, the present 
study investigated the effect of combination of 
melatonin and vitamin C on learning and memory in 
scopolamine-induced rat model of cognitive 
impairment.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
MATERIALS AND METHODS 
Drugs and reagents 
All chemicals/drugs and reagents used were of analytical 
grade and drug solutions were freshly prepared before 
use. Scopolamine was a product of Hubei Tianyao 
pharmaceutical Co. Ltd. Hubei, China. Donepezil was 
produced by Torrent Pharma Ltd, United Kingdom. 
Ketamine and Melatonin were purchased from Sigma 
chemical company (St. Louis, MO, USA). Vitamin C 
(Biopharma Nigeria Ltd) was purchased from 
Aromokeye Pharmacy, Ilorin, Nigeria. The drugs were 
dissolved in normal saline and administered based on 
body weight. 
 
Table 1: Animal grouping and administration 
Groups Dosage administered to each group (daily) 
1         Control Vehicle (5 ml/kg normal saline) orally 
2         Scopolamine treated Scopolamine (1mg/kg) ip. 
3         Donepezil treated Scopolamine (1mg/kg) ip. + Donepezil (2mg/kg) orally 
4         Scopolamine/Melatonin  Scopolamine (1mg/kg) ip. + Melatonin (10mg/kg) orally. 
5         Scopolamine/Vitamin C  Scopolamine (1mg/kg) ip. + Vitamin C (100mg/kg) orally. 





Thirty male Wistar rats with an average weight of 125g 
were obtained from the breeding colony of Department 




housed in cages and fed with standard diet and water ad 
libitum, in the   animal holding of   the Faculty of Basic 
Medical Sciences, College of Health Sciences,  
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University of Ilorin, Ilorin. The rats were kept under 
standard laboratory conditions (12h light/dark cycle, 
temperature: 22 ± 3oC) and acclimatized for two weeks 
before the commencement of the experiment. The 
experiment was performed in compliance with NIH 
guidelines for the humane use of laboratory animal. 
 
The experiment was conducted in the morning (between 
the hours of 08:00 and 10:00). Administration of 
treatments regimen as shown above lasted for 15 
consecutive days. Cognitive impairment was induced in 
all groups except control by a daily single injection of 
scopolamine (1 mg/kg, i.p). One-hour post scopolamine 
injection, rats were administered either donepezil, 
melatonin, vitamin C or a combination of melatonin and 
vitamin C. On the last day of administration, Morris 
water maze (MWM) and modified light and dark box 
were used to assess spatial memory function. Thereafter, 
each rat was anaesthetized, the brain was excised and 
then homogenized. The supernatant was processed for 
biochemical analysis of malondialdehyde (MDA), 
reduced glutathione (GSH) and Acetylcholinesterase. 
Behavioral Tests 
Morris Water-Maze Test 
Spatial memory was evaluated using the Morris water 
maze (Morris, 2008). The maze is made up of an open 
circular pool of about 200 cm in diameter and 70cm deep 
filled with water up to about 60cm of the pool. A hidden 
platform with a top surface of about 15cm, maintained 
at the same position throughout the experiment was 
submerged at about 1.5cm below the water surface. The 
platform was made hidden by adding milk to make the 
water opaque thereby creating a nearly invisible 
platform-to-background. First, animals were trained to 
locate the platform. The maximum cut off duration for 
swimming was set at 60 seconds. When the rat locates 
the invisible platform the timer was stopped and the rat 
was removed but if the rat did not find the platform 
during the allotted time, the rat was guided on to the 
platform. At the end of the trial, the rats were removed 
from water, dried with towel and placed back in their 
home cages to keep warm. During acquisition trial, 
escape latency time (ELT), time taken to locate the 
hidden platform, was noted as an index of learning 
which was recorded with the aid of a video system. Each 
animal was subjected to the four acquisition trials per 
day for 5 consecutive days before the administration. On 
the last day of administration (15th day), the animals 
were re-exposed to the maze (to test for their spatial and 
long-term memory functions), a video camera was 
placed above the center of the pool to capture images of 
the swimming animal, for measures of the escape 
latency. The time spent by the animal in locating the 
hidden platform (escape latency) was noted as an index 
of learning. At the end of the test, the rats were removed 
from water, dried with towel and placed back in their 
home cages to keep warm. 
 
Light and dark box 
The light and dark box, an apparatus normally use for 
mood assessment was modified to evaluate spatial 
memory (Ayinla et al., 2019). The tool consists of two 
compartments, the light and dark section. The light and 
dark box used was 50cm x 30cm x 100cm in size and the 
two sections were linked with an opening of 8cm2. 
Before administration, the rats were trained three trials a 
day (5 minutes per trial) for three consecutive days. At 
the end of training, only animals that developed memory 
of an opening route between the light and dark 
compartments were used for the experiment. To 
establish formation of memory in rats, the opening route 
was blocked from the dark compartment using black 
plank. Animals were then reintroduced and allowed to 
move freely, increased probing of the blocked-exit 
showed memory formation. One hour after the last 
treatments on day 15, the rats were re-introduced to the 
modified light and dark box and could explore the maze 
for 5 minutes. This was recorded with an overhead 
camera (Logtech Webcam, 5MP) and later analyzed by 
a blinded investigator. The number of time (frequency) 
each rat probed the blocked aperture was documented as 
the index for intact/enhanced spatial memory. 
 
Sample Collection 
On the 15th day of administration, after behavioral 
assessments, the rats were anaesthetized with 
intraperitoneal injection of ketamine (100 mg/kg). The 
brain tissues were isolated weighed and homogenized in 
0.1 M phosphate buffer solution (pH 7.4). The 
homogenate was centrifuged at 3000 rpm for 10 minutes 
and the supernatant were separated and kept at -20 ͦ C 
prior to biochemical analysis. 
 
Biochemical Analysis 
Estimation of Acetylcholine esterase (AchE) level 
The cholinergic marker, acetylcholinesterase, was 
estimated using Acetylcholinesterase Activity Assay kit 
(Elabscience, China). The assay kit is an optimized 
version of Ellman’s method (Ellman, 1961) in which 
thiocholine, produced by AChE, reacts with 5, 5-
dithiobis (2-nitrobenzoic acid). This homogenate was 
incubated for 5 min with 2.7mL of phosphate buffer and 
0.1ml of Ellman's reagent (5, 5-dithiobis 2-
nitrobenzoate, DTNB). Then, 0.1ml of freshly prepared 
acetylthiocholine iodide (pH 8) was added and the 
absorbance was read at 412nm. 
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Estimation of Malondialdehyde (MDA) level 
Malondialdehyde (MDA), marker of oxidative stress 
was indirectly estimated by determining the 
accumulation of thiobarbituric acid reactive substances 
(TBARS) based on the method of Mihara and Uchiyama, 
(1978). Briefly, 3 ml of 1% H3PO4 and 1 ml of 0.6% 
TBA aqueous solution were added to 0.5 ml of 10% 
homogenate of the tissue sample. It was stirred and the 
mixture was heated on a boiling water bath for 45 
minutes and allowed to cool. After which 4 ml of n-
butanol was added, shook and the butanol layer was 
separated by centrifugation. The optical density was read 
at 535 and 520 nm 
 
Estimation of reduced glutathione (GSH) level  
Reduced glutathione was assayed according to the 
method of Ellman (1959). The colorimetric assay 
involves carefully optimized enzymatic recycling 
method using glutathione reductase and Ellman’s 
reagent; DTNB. Glutathione reductase reduces GSSG to 
GSH. DTNB (5-5-dithiobis (2-nitrobenzoic acid) reacts 
with GSH to form yellow colour chromophore, 5 – 
thionitrobenzoic acid (TNB) and GS- TNB. GS – TNB 
was further reduced to GSH and TNB by glutathione 
reductase. The absorbance was read at 415nm and 
compared with standard curve for GSSG. 
 
Statistical Analysis 
The results were expressed as mean ± standard error of 
mean (SEM). Statistical significance was done using 
one-way analysis of variance (ANOVA) and then 
subjected to post-hoc Newman-Keul test using Graph 
pad prism version 5. Values were considered statistically 




Effects of melatonin and vitamin C on escape latency in 
Morris water maze test: 
In Fig 1, the scopolamine-treated group showed an 
increase Escape Latency (EL) compared with control 
group which is an indicator of cognitive impairment (as 
this group of rats took a longer time to identify the 
escape platform).  
Treatment with donepezil (reference drug), melatonin 
or/and vitamin C enhanced memory function as depicted 
by a significant (p<0.05) decrease in EL when compared 
with the group that received scopolamine only. 
Furthermore, there was no significant difference in EL 
in rats treated with melatonin or/and vitamin C when 
compared with donepezil treated group. Also, there was 
no significant difference in between the intervention 
groups as they show similar pattern. 
 
Effects of melatonin and vitamin C on probing frequency 
in modified light and dark box: 
As shown in Fig 2, there was a significant (p<0.05) 





Fig.  1. Effects of melatonin and vitamin C on escape latency 
in Morris water maze test. Values are expressed as mean ± 
SEM of 5 rats per group. F (5, 29) = 48.10; #p<0.05 vs Control 
group, *p<0.05 vs scopolamine treated group Scop = 




Fig 2. Effects of melatonin and vitamin C on probing 
frequency in light and dark box. Values are expressed as mean 
± SEM of 5 rats per group. F (5, 29) = 78.33.  #p<0.05 vs 
Control, *p<0.05 vs Scopolamine treated group. Scop = 
scopolamine, DON= donepezil, Vit.C = vitamin C, MEL= 
melatonin  
 
the rat visited the escape route/aperture) in the 
scopolamine-treated rats when compared with control 
rats. Intervention with melatonin or/and vitamin C 
caused a significant increase in the probing frequency 
compared with scopolamine group. However, there was 
no significant difference in the probing frequency 
between the rats treated with donepezil (reference drug) 
and the three intervention groups. Also, there was no 
significant difference in between the intervention groups 
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Effects of melatonin and vitamin C on acetylcholine 
esterase (AchE) activity: 
In Fig 3, the activity of AchE (an enzyme which breaks 
down Ach neurotransmitter) was significantly increased 
 
Fig 3. Effects of melatonin and vitamin C on acetylcholine 
esterase (AchE) activity. Values are expressed as mean ± SEM 
of 5 rats per group.  F (5, 29) = 224.6; #p<0.05 vs control 
group, *p<0.05 vs Scopolamine treated group. Scop = 
scopolamine, DON= donepezil, Vit.C = vitamin C, MEL= 
melatonin  
 
Fig. 4. Effects of melatonin and vitamin C on 
malondialdehyde (MDA) level. Values are expressed as mean 
± SEM of 5 rats per group. F (5, 29) = 21.84; #p<0.05 vs 
control group, *p<0.05 vs Scopolamine treated group. Scop = 
scopolamine, DON= donepezil, Vit.C = vitamin C, MEL= 
melatonin  
 
in the scopolamine group when compared with control 
group. Conversely, administration of melatonin or/and 
vitamin C reduced its activity when compared with the 
scopolamine group. The reduction in the activity of 
AchE in the combined treatment group follow a similar 
pattern with the donepezil treated group. However, there 
was no significant difference in between the intervention 
groups. 
 
Effects of melatonin and vitamin C on malondialdehyde 
(MDA) level: 
Fig 4 shows   that the level  of MDA,   an index of lipid                                                                                         
peroxidation, was significantly increased in scopolamine 
group when compared with control. Treatment with 
melatonin or/and Vitamin C significantly (p<0.05) 
attenuated the level of MDA compared with the 
untreated scopolamine group. There was no significant 
difference in MDA level across the three intervention 




Fig. 5: Effects of melatonin and vitamin C on reduced 
glutathione (GSH) level. Values are expressed as mean ± SEM 
of 5 rats per group. F (5, 29) = 11.73;  #p<0.05 vs control 
group, *p<0.05 vs Scopolamine treated group. Scop = 
scopolamine, DON= donepezil, Vit.C = vitamin C, MEL= 
melatonin  
 
Effects of melatonin and vitamin C on reduced 
glutathione (GSH) level: 
In Fig 5, the scopolamine group showed a significant 
decrease in the level of GSH compared with control rats. 
Conversely, administration of melatonin and Vitamin C 
led to a significant (P<0.05) increase in GSH when 
compared with scopolamine group. Also, the level of 
GSH in the three intervention groups compare favorably 
with donepezil treated rats and control group. However, 





Antioxidant used as a potential treatment for cognitive 
impairment has been of interest for many years. Studies 
report that oxidative stress is positively associated with 
impaired cognitive function. Multiple lines of evidence 
demonstrate beneficial effects of antioxidants on 
cognition and dementia (Farah et al., 2016). 
Several drug induced dementia models have been used 
to evaluate the effects and therapeutic potentials of novel 
drugs in dementia; these include colchicine, 
scopolamine, okadaic acid and trimethyltin (Malekzadeh 
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et al., 2017). Scopolamine model used in this study has 
been reported to antagonize acetylcholine activities, 
increase brain oxidative stress status and impair learning 
and memory functions similar to memory deficit 
observed in dementia (Bubser et al., 2012; Falsafi et al., 
2012; Gil-Yong et al., 2017). Furthermore, the use of 
acetycholine esterase (AchE) inhibitors such as Tacrine, 
donepezil, and rivastigmine has been approved for the 
treatment of dementia symptoms (Amenta and Tayebati, 
2008). Donepezil used in the present study as a reference 
drug is a known acetycholine esterase inhibitor which 
increases acetylcholine concentration and up-regulate 
brain cholinergic receptors (Cacabelos, 2007). Ketamine 
was used as an anesthetic agent in this study. Chronic 
administration of ketamine in animal model of 
schizophreina has been shown to increase AChE level in 
brain tissues which leads to cognitive deficit (Zugno et 
al., 2014). This might not affect the present result as it 
was administered at a sub-chronic dose once and across 
all the groups. 
 
In this study, the significant decrease in the escape 
latency recorded in the group treated with melatonin and 
vitamin C shows the memory-enhancing effect of the 
drugs. This confirms the reports of Xia et al., (2016). 
Although these authors used isoflurane to induce 
impairment of spatial memory. Also our results are in 
conformity with the findings of Olcese et al., (2009). 
Similarly, the increase in the frequency of visiting the 
blocked escape route (modified light and dark box test) 
by rats treated with melatonin, vitamin C and 
combination of melatonin and vitamin C is suggestive of 
improvement in cognitive impairment. Furthermore, the 
observed improvement in the cognitive decline is 
consistent with the report of Tongjaroenbuangam et al. 
wherein pre-treatment with melatonin prior to 
dexamethasone-induced memory deficit resulted in 
shorter escape latencies and a longer time spent in the 
target quadrant which implies an improvement in 
memory function (Tongjaroenbuangam et al., 2013). 
However, in contrast to our own finding, a study by 
Yilmaz et al., (2015) in which melatonin was given 
together with vitamin C, showed no reversal of memory 
deficit in a dexamethasone-induced model of cognitive 
impairment in rats. Also, earlier studies using the AD 
model showed improvement in cognitive function (Xian 
et al., 2002). However, a study by Eslamizade et al. 
(2016) showed no effect of melatonin on the cognitive 
function despite its protective effects against Aβ-
induced increase in NF-κB and shrinkage of the CA1 
pyramidal neurons. The disparity between these reports 
and ours may be attributed to differences in the 
melatonin dose, route and duration of administration, 
age of animal, and method of inducting cognitive 
impairment.  
 
Scopolamine has been reported to elevate 
acetylcholinesterase (AChE) levels in the cortex and 
hippocampus (Ahmed and Gilani, 2009). The data 
obtained from this study showed that the 
acetylcholinesterase activity was reduced in melatonin 
and vitamin C treated groups similar to donepezil which 
show that melatonin and vitamin C inhibited the action 
of acetylcholinesterase. This action could enhance 
cholinergic transmission and thus availability of 
acetylcholine at the synapse. Meanwhile, acetylcholine 
is an important neurotransmitter which is involved in 
memory consolidation (Feng et al., 2004). 
 
Elevated level of malondialdehyde recorded in the 
scopolamine rats agree with the study which showed that 
impairment of memory in scopolamine induced animal 
model is associated with altered status of brain oxidative 
stress (Roja et al., 2017). As such, the significant 
decrease in the MDA level of groups treated with 
melatonin and vitamin C may be attributed to their 
antioxidant properties. These antioxidants protect brain 
cells from oxidative stress; thereby reducing brain 
damage and improved neuronal function. 
Epidemiological and laboratory findings reveal that 
antioxidants delay progress of neurodegenerative 
disease such as Alzheimer’s disease probably due to 
prevention or neutralization of detrimental effects of free 
radicals (Small and Mayeu, 2002). Similarly, the low 
level of reduced glutathione recorded in scopolamine-
treated rats confirms the findings of Reiter et al. (2007) 
wherein high oxidative stress was accompanied by 
reduction in total glutathione levels. Therefore, the 
significant increase in GSH level of melatonin and 
vitamin C treated groups as compared to the 
scopolamine group may be due to their ability to 
promote the activity of antioxidant enzymes (Kurutas, 
2016; Najafi et al., 2017).  
 
The central nervous system is vulnerable to free radical 
damage because of the brain’s high oxygen 
consumption, its abundant lipid content, and the relative 
paucity of antioxidant enzymes as compared to other 
tissues. The brain is deficient in oxidative defense 
mechanisms and hence is at greater risk of damage 
mediated by reactive oxygen species (ROS), resulting in 
cellular dysfunction (Gupta et al., 2003). Oxidative 
stress has been demonstrated to be related to the 
pathophysiologic mechanisms involved in brain injury 
in various common neurodegenerative disorders, 
including Parkinson’s, Alzheimer’s and Huntington’s 
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diseases. Oxidative stress decreases the antioxidant 
defense status in the brain, which may form the basis for 
impaired memory (Onodera et al., 2003). Thus, in the 
present study, the memory deficits observed in 
scopolamine-treated rats might have resulted from 
increased free radical formation and subsequent 
oxidative injury to neurons. Oxygen free radicals and 
other products of oxidative metabolism have been shown 
to be neurotoxic. Studies have shown that 
dehydroascorbic acid, the oxidized form of ascorbic 
acid, enters the brain by means of facilitated transport 
(Agus et al., 1997). GLUT-1 transporter present on the 
endothelial cells of the blood-brain barrier helps in the 
transport of glucose and dehydroascorbic acid into the 
brain (Huang et al., 2001). Oral administration of 
ascorbic acid might have resulted in the entry of high 
levels of dehydroascorbic acid into the rat’s brain, which 
could protect neurons from the deleterious effects of free 
radicals. Administration of Melatonin or/and vitamin C 
improved learning and memory deficits by inhibiting 
oxidative stress via reduction of lipid peroxidation as 
depicted by low level of MDA, elevating oxidized 
glutathione (GSH) levels, and by modulating cholinergic 
neurotransmission.  Similarly, the improvement in the 
cognitive behavioral decline can be attributed to 
enhanced neural plasticity mediated by the preservation 
of Ach, a key neurotransmitter involved in the process 
of learning and memory (Feng et al., 2004). The 
reduction in the activities of acetylcholinesterase is 
thought to have increased the concentration of Ach, 
hence its availability for neurotransmission. Melatonin 
reportedly improved cognitive functions by increasing 
the number or activity of ChAT in the brain (Xian et al., 
2002; Eltablawy and Tork, 2014). It is worthy of 
mention that intervention with melatonin + vitamin C 
did not improve cognitive impairment better than the 
groups that received either melatonin or vitamin c alone. 
The melatonin + vitamin c group compares favorably 
with other treatment groups. 
 
CONCLUSION 
Co-administration of melatonin and vitamin C improved 
cognitive impairment by modulation of oxidative stress 
pathway and enhancement of cholinergic 
neurotransmission. As such, a combination of melatonin 
and vitamin C could provide ameliorative effect in 
neurological disorders where cognition is impaired.  
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